SAB BIOTHERAPEUTICS, INC.
SABS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SABS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SABS
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific, high-potency human immunoglobulin G (hIgG) therapies for immune and autoimmune disorders, leveraging a proprietary platform that does not require human donors or convalescent plasma.
Key risk: Continued operating losses
BioSniper Score
Based on 5 of 6 signals
Market Cap
$344.8M
Cash Runway
30.3 moLead Asset
sab-142 (Phase 2)
Next Catalyst
Phase3_Topline · Aug 1, 2029Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 13 clinical trials · 2 catalysts for SAB BIOTHERAPEUTICS, INC..
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific, high-potency human immunoglobulin G (hIgG) therapies for immune and autoimmune disorders, leveraging a proprietary platform that does not require human donors or convalescent plasma.
- Clinical-stage biopharmaceutical company focused on multi-specific, high-potency hIgG therapies for immune and autoimmune disorders [sec_mda · as of 2026-08-06].
- Lead product candidate is SAB-142, currently being advanced through Phase 2 clinical trials [sec_mda · as of 2026-05-12].
- Cash and equivalents of $8.3M as of 2026-06-30 [sec].
- Accumulated deficit of $152.3M as of 2026-06-30 [sec_mda · as of 2026-08-06].
- Net loss of -$22.5M for the six months ended 2026-06-30 [sec].
What works
- Proprietary platform enables production of high-titer, high-avidity human antibodies without reliance on human donors or convalescent plasma, potentially offering a scalable and consistent supply [sec_mda · as of 2025-05-09].
- hIgG therapeutics have demonstrated safety in Phase 3 clinical trials with a patient safety database of over 700 patients [sec_mda · as of 2025-05-09].
- Established regulatory pathways with FDA, CBER, MHRA, and TGA, indicating familiarity with the company's multivalent and multitarget product properties [sec_mda · as of 2025-05-09].
What to weigh
- Accumulated deficit of $152.3M as of 2026-06-30, with expectations of continued operating losses for the foreseeable future [sec_mda · as of 2026-08-06].
- Cash used in operating activities increased by $9.2M in the six months ended June 30, 2026, compared to the same period in 2025, driven by investment in lead candidate SAB-142 [sec_mda · as of 2026-08-06].
- Net loss of -$22.5M for the six months ended 2026-06-30, with cash of only $8.3M, indicating potential need for additional capital to fund operations [sec].
From the filings
Quoted directly from source documents.
Company focus on multi-specific, high-potency hIgG therapies
“We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders.”
SEC MD&A · August 6, 2026
Lead product candidate SAB-142
“The year-over-year increase in cash used reflects working capital fluctuations as we continue to invest in the development of our lead product candidate, SAB-142.”
SEC MD&A · May 12, 2026
Accumulated deficit
“As of June 30, 2026, we had an accumulated deficit of $152.3 million.”
SEC MD&A · August 6, 2026
Safety database from Phase 3 trials
“Our hIgGs have been safely demonstrated in Phase 3 clinical trials with a patient safety database that includes over 700 patients who were safely administered our hIgG therapeutics.”
SEC MD&A · May 9, 2025
Catalyst timeline
- 2029-08-01 · Phase3_Topline — Phase 3 Topline: Efficacy and Safety of Gene Therapy rAAV-RPE65 (LX101) in Biallelic RPE65 Mutation-associated Inheri — Topline results from a Phase 3 trial of gene therapy rAAV-RPE65 (LX101) for biallelic RPE65 mutation-associated inherited retinal disease.
- 2032-06-04 · Phase3_Topline — Phase 3 Topline: A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of — Topline results from a Phase 3 randomized, open-label, active-controlled study evaluating efficacy and safety of an unspecified therapy.
Risks & what to watch (3)›
Key risks
- Continued operating losses — Company expects to continue incurring operating losses for the foreseeable future, with accumulated deficit of $152.3M as of 2026-06-30 [sec_mda · as of 2026-08-06].
- Need for additional capital — Cash of $8.3M as of 2026-06-30 may be insufficient to fund operations without further capital raises [sec].
- Clinical development risk — Lead candidate SAB-142 is still in Phase 2 trials; failure could materially impact the company [sec_mda · as of 2026-05-12].
What to watch
- Progress of lead candidate SAB-142 through Phase 2 clinical trials [sec_mda · as of 2026-05-12].
- Cash burn rate and potential need for additional financing given $8.3M cash as of 2026-06-30 [sec].
- Regulatory interactions with FDA, CBER, MHRA, and TGA for pipeline candidates [sec_mda · as of 2025-05-09].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run SAB BIOTHERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SAB BIOTHERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
30.3 months
D/E 0.11 · 0% dilution
Lead: Phase 2
1 candidate
2 upcoming, next in ~1067d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
77
Total value held
$246.5M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 12,863,486 | $49.3M |
| caligan partners lp | 7,967,207 | $30.5M |
| vanguard capital management llc | 4,987,474 | $19.1M |
| commodore capital lp | 4,401,500 | $16.9M |
| ra capital management, l.p. | 4,401,500 | $16.9M |
| balyasny asset management l.p. | 3,760,439 | $14.4M |
| adage capital partners gp, l.l.c. | 3,405,553 | $13.0M |
| millennium management llc | 3,032,697 | $11.6M |
| spruce street capital lp | 2,198,502 | $8.4M |
| sessa capital im, l.p. | 2,198,457 | $8.4M |
Showing top 10 of 77 institutional holders of SAB BIOTHERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 3.6%
- Days to cover
- 5.7
- Shares short
- 2,418,434
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SABS short interestGovernance
Frequently asked questions
What is the AI investment thesis for SAB BIOTHERAPEUTICS, INC.?
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing multi-specific, high-potency human immunoglobulin G (hIgG) therapies for immune and autoimmune disorders, leveraging a proprietary platform that does not require human donors or convalescent plasma.
What is SAB BIOTHERAPEUTICS, INC.'s lead drug candidate?
SAB BIOTHERAPEUTICS, INC.'s most advanced tracked candidate is sab-142 (Phase 2) for Type 1 Diabetes.
What is SAB BIOTHERAPEUTICS, INC.'s next catalyst?
SAB BIOTHERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Efficacy and Safety of Gene Therapy rAAV-RPE65 (LX101) in Biallelic RPE65 Mutation-associated Inheri" — expected August 1, 2029.
Who is the CEO of SAB BIOTHERAPEUTICS, INC.?
Mr. Samuel J. Reich is the chief executive officer of SAB BIOTHERAPEUTICS, INC. (SABS).
Where is SAB BIOTHERAPEUTICS, INC. headquartered?
SAB BIOTHERAPEUTICS, INC. (SABS) is headquartered in Miami Beach, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.